Comparative study to assess effectiveness and Safety of Amlodipine and Telmisartan.
Not Applicable
- Conditions
- Health Condition 1: I10- Essential (primary) hypertension
- Registration Number
- CTRI/2024/02/062389
- Lead Sponsor
- Dr Reddys Laboratories Ltd
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Treatment-naïve patients with essential or primary hypertension.
Patients who were prescribed amlodipine or telmisartan monotherapy as first line therapy.
Exclusion Criteria
Patients with secondary hypertension.
Patients prescribed with any other antihypertensive drug
Patients prescribed with any combination of antihypertensive drugs
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change in SBP and DBP from baseline to 12 weeks.Timepoint: An interim visit of 2 weeks and a final visit of 12 weeks will be considered for analysis.
- Secondary Outcome Measures
Name Time Method Change in heart rate and assessment of pedal edemaTimepoint: Baseline to 2, and 12 weeks.